Business Context and Reporting Period
Company: Immatics N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Immatics is a clinical-stage biopharmaceutical company focused on developing T cell receptor (TCR)-based immunotherapies targeting the PRAME antigen for cancer treatment. The company operates primarily in Germany and the United States with no products currently approved for commercial sale. Revenue is derived exclusively from strategic collaboration agreements.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (€ millions) | 2024 (€ millions) |
|---|---|---|
| Revenue | 48.3 | 155.8 |
| Net Loss | (196.4) | 15.2 (Profit) |
| Operating Loss | (182.0) | (38.6) |
| Research & Development Expenses | (183.8) | (148.1) |
| Cash and Cash Equivalents | 345.9 | 236.7 |
| Total Financial Assets (Cash + Deposits) | 469.3 | 604.5 |
| Accumulated Deficit | (786.0) | (589.5) |
Note: The 2024 net profit was primarily driven by the recognition of deferred revenue from terminated collaboration agreements and a significant gain from the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 69% (€107.5 million) compared to 2024. This was due to the termination of collaboration agreements with Genmab, BMS (IMA401), and BMS (Allo) in 2024, which resulted in a one-time recognition of remaining deferred revenue in the prior year. 2025 revenue reflects ongoing cost-to-cost recognition from active agreements with Moderna and BMS.
- Return to Loss: The company returned to a net loss position in 2025 (€196.4 million) after reporting a net profit in 2024. The 2024 profit was non-recurring, driven by the derecognition of deferred revenue from terminated deals and a €17.3 million gain from warrant liability fair value changes. In 2025, warrant liabilities were derecognized upon expiration, and operating expenses increased.
- Increased R&D Spend: R&D expenses increased by 24% (€35.8 million) to €183.8 million, driven by increased clinical trial activities for the lead candidate anzu-cel (SUPRAME Phase 3 trial) and the second-generation IMA203CD8.
- Foreign Exchange Impact: Significant unrealized foreign exchange losses (€35.7 million) impacted the financial result in 2025 due to the strengthening of the Euro against the U.S. Dollar, affecting USD-denominated cash holdings.
Guidance, Outlook, and Management Commentary
- Liquidity: Management states that cash and cash equivalents of €345.9 million, plus other financial assets, are sufficient to fund operations for at least the next 12 months. The company raised €100.1 million in net proceeds from a public offering in December 2025.
- Clinical Milestones (2026-2027):
- anzu-cel (IMA203): Interim and final data analyses for the Phase 3 SUPRAME trial are expected in 2026. Biologics License Application (BLA) submission is targeted for H1 2027, with a potential U.S. market launch in H2 2027.
- IMA203CD8: Data update for ovarian cancer expected in H1 2026; Recommended Phase 2 Dose (RP2D) determination expected in 2026.
- IMA402 (Bispecific): RP2D determination and Phase 1 data update expected in H2 2026.
- Manufacturing: The company commenced GMP manufacturing at its new 100,000 sq. ft. facility in Stafford, Texas, in 2025 to support late-stage trials and initial commercial supply.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the complexity of manufacturing personalized cell therapies, reliance on third-party CMOs for bispecifics, and the need for additional capital to sustain operations beyond the current runway.
Important Facts for Investor Verification
- Revenue Sustainability: Verify the sustainability of revenue streams given the termination of major collaboration agreements in 2024 and the reliance on cost-to-cost recognition for remaining deals.
- Cash Burn Rate: Assess the operating cash burn (€176.6 million used in operating activities in 2025) against the current cash balance to confirm the 12-month liquidity runway.
- Currency Exposure: Monitor the impact of EUR/USD exchange rate fluctuations on the financial statements, as the company holds significant USD assets but reports in EUR.
- Regulatory Pathway: Confirm the status of the SUPRAME Phase 3 trial enrollment and the timeline for the BLA submission, as this is the primary path to commercialization.
- PFIC Status: Note that the company believes it was a Passive Foreign Investment Company (PFIC) for the 2025 tax year, which may have adverse tax consequences for U.S. investors.